Clicky

Innate Pharma(IPHYF)

Description: Innate Pharma specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by enhancing the capability of the body's own immune cells to recognize and kill cancer cells.The Company has pioneered the development of antibodies that block inhibitory checkpoint receptors on NK cells. Today, Innate Pharma has three first-in-class antibodies in clinical development in immuno-oncology and a pipeline of preclinical candidates to novel targets and mechanisms.Its innovative approach has translated into alliances with leaders in the biopharmaceutical industry such as AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S and Sanofi.Based in Marseille, France, Innate Pharma had 122 employees as at March 31, 2016. The company is listed on Euronext Paris.


Keywords: Cancer Life Sciences Immune System Antibodies Cancer Treatment Cancer Immunotherapy Euronext Slate Myer Natural Killer Cell Compugen Biopharmaceutical Industry Euronext Paris Eric Vivier

Home Page: www.innate-pharma.com

117, Avenue de Luminy
Marseille, 13009
France
Phone: 33 4 30 30 30 30


Officers

Name Title
Dr. Mondher Mahjoubi M.D. Chairman of Exec. Board & CEO
Mr. Yannis Morel Ph.D. Exec. VP of Product Portfolio Strategy & Bus. Devel. and Member of Exec. Board
Dr. Herve Brailly Co-Founder & Chairman of Supervisory Board
Dr. François Romagné Ph.D. Founder
Mr. Eric Vivier D.V.M., M.B.A., Ph.D. Founder, Sr. VP & Chief Scientific Officer
Dr. Marc Bonneville Ph.D. Founder
Mr. Jean Jacques Fournié Ph.D. Founder
Mr. Alessandro Moretta M.D., Ph.D. Founder
Mr. Frederic Lombard M.B.A. Sr. VP & CFO
Ms. Odile Belzunce VP of Compliance & Operations

Exchange: PINK

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 1.4757
Price-to-Sales TTM: 3.2659
IPO Date:
Fiscal Year End: December
Full Time Employees: 213
Back to stocks